D evelopment of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone

被引:17
作者
Shillington, Alicia C. [1 ]
Col, Nananda [2 ]
Bailey, Robert A. [3 ]
Jewell, Mark A. [1 ]
机构
[1] EPI Q Inc, Oak Brook, IL 60523 USA
[2] Shared Decis Making Resources, Georgetown, ME USA
[3] Janssen Sci Affairs LLC, Raritan, NJ USA
来源
PATIENT PREFERENCE AND ADHERENCE | 2015年 / 9卷
关键词
patient decision aid; shared decision-making; type; 2; diabetes; ADHERENCE; PHYSICIANS; FRAMEWORK; OUTCOMES; QUALITY; HEALTH; IMPACT;
D O I
10.2147/PPA.S82555
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To describe the process used to develop an evidence-based patient decision aid (PDA) that facilitates shared decision-making for treatment intensification in inadequately controlled type 2 diabetes mellitus (T2DM) consistent with International Patient Decision Aids Standards. Methods: A PDA was developed by a multidisciplinary steering committee of clinicians, patient advocate, nurse, certified diabetes educators, and decision scientist, using a systematic development process. The process included defining the PDA scope and purpose, outlining the framework, content creation, and designing for integration into clinical practice. This was accomplished through a review of the literature and publically available educational materials and input from practicing clinicians and patients during development and iteratively refining content based on input. Patients with poorly controlled T2DM on metformin considering additional medication assessed the PDA during a pilot. Results: Testing identified six preference-sensitive domains important for choosing T2DM treatment: degree of glycemic response, avoiding weight gain, hypoglycemia risk and other adverse events, avoiding injections, convenience of dose administration, blood glucose monitoring, and cost of therapy. Patient feedback guided content revision. Treatment options were offered after presenting medication class risk-benefit information and eliciting patient values, goals, and preferences. The PDA received the highest International Patient Decision Aids Standards global score to date, 88/100, with 100% of criteria fully met for the following dimensions: development process, disclosures, evaluation process, evidence quality, guidance for users, information quality, language/readability, testing, and eliciting patient values. Conclusion: A PDA was developed to help T2DM patients make decisions regarding medication choice. This approach may be applicable to other chronic conditions.
引用
收藏
页码:609 / 617
页数:9
相关论文
共 50 条
  • [41] Comparison of Effects of Gliclazide, Metformin and Pioglitazone Monotherapies on Glycemic Control and Cardiovascular Risk Factors in Patients with Newly Diagnosed Uncontrolled Type 2 Diabetes Mellitus
    Erem, C.
    Ozbas, H. M.
    Nuhoglu, I.
    Deger, O.
    Civan, N.
    Ersoz, H. O.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2014, 122 (05) : 295 - 302
  • [42] Type 2 diabetes mellitus, glycemic control, and cancer risk
    Onitilo, Adedayo A.
    Stankowski, Rachel V.
    Berg, Richard L.
    Engel, Jessica M.
    Glurich, Ingrid
    Williams, Gail M.
    Doi, Suhail A.
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2014, 23 (02) : 134 - 140
  • [43] The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*
    Yang, Wenying
    Guan, Yanfen
    Shentu, Yue
    Li, Zhi
    Johnson-Levonas, Amy O.
    Engel, Samuel S.
    Kaufman, Keith D.
    Goldstein, Barry J.
    Alba, Maria
    JOURNAL OF DIABETES, 2012, 4 (03) : 227 - 237
  • [44] Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus
    Mitchell, Beth D.
    Eby, Elizabeth L.
    Lage, Maureen J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (12) : 1587 - 1597
  • [45] Anti oxidant potential of Metformin and Pioglitazone in Type 2 Diabetes Mellitus: Beyond their anti glycemic effect
    Singh, R. K.
    Gupta, B.
    Tripathi, K.
    Singh, S. K.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2016, 10 (02) : 102 - 104
  • [46] Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets
    Dalal, Mehul R.
    Grabner, Michael
    Bonine, Nicole
    Stephenson, Judith J.
    DiGenio, Andres
    Bieszk, Nella
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 121 : 17 - 26
  • [47] Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus
    Kothny, W.
    Foley, J.
    Kozlovski, P.
    Shao, Q.
    Gallwitz, B.
    Lukashevich, V.
    DIABETES OBESITY & METABOLISM, 2013, 15 (03) : 252 - 257
  • [48] The contribution of metformin to glycaemic control in patients with Type 2 diabetes mellitus receiving combination therapy with insulin
    Tong, PC
    Chow, CC
    Jorgensen, LN
    Cockram, CS
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2002, 57 (02) : 93 - 98
  • [49] The effectiveness of patient activation intervention on type 2 diabetes mellitus glycemic control and self-management behaviors: A systematic review of RCTs
    Almutairi, Nasser
    Hosseinzadeh, Hassan
    Gopaldasani, Vinod
    PRIMARY CARE DIABETES, 2020, 14 (01) : 12 - 20
  • [50] Effect of the statin choice encounter decision aid in Spanish patients with type 2 diabetes: A randomized trial
    Perestelo-Perez, Lilisbeth
    Rivero-Santana, Amado
    Boronat, Mauro
    Sanchez-Afonso, Juan A.
    Perez-Ramos, Jeanette
    Montori, Victor M.
    Serrano-Aguilar, Pedro
    PATIENT EDUCATION AND COUNSELING, 2016, 99 (02) : 295 - 299